Nuo Therapeutics, Inc.
No SEC Form 4 filings for $AURX in the last 30 days.
See all $AURX insider activity →Nuo Therapeutics, Inc. (AURX) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99 2 ex_1005708.htm EXHIBIT 99 ex_1005708.htm Exhibit 99 8285 El Rio, Suite 190 Houston, TX 77054 Phone 833.298.6633 NUO THERAPEUTICS ANNOUNCES SECOND QUARTER 2026 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE Differentiated Autologous PRP Remains Well-Positioned for Attracti
HOUSTON, April 29, 2025 ( GLOBE NEWSWIRE ) -- Nuo Therapeutics, Inc. ( OTCQB: AURX ) ( "Nuo" ) , a commercial stage medical device company pioneering leading-edge biodynamic therapies by focusing on emerging opportunities in the evolving healthcare landscape, announced it has entered into an ...
Over the past 7 days, alphai's AI scored 1 news story mentioning AURX (Nuo Therapeutics, Inc.). Coverage has skewed bullish: 1 bullish, 0 neutral, and 0 bearish.
Recent AURX coverage spans earnings and financial news.
The filing combines accelerating sales momentum with improved operating loss and additional near-term liquidity, while highlighting Medicare reimbursement rulemaking that could support demand.
The announcement of a distribution agreement with Smith+Nephew is positive for Nuo Therapeutics, potentially enhancing sales channels and revenue streams.
alphai scores every news story that mentions AURX with an AI model for sentiment and relevance, and aggregates insider trades from Nuo Therapeutics, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Nuo Therapeutics, Inc. (AURX) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99 2 ex_1005708.htm EXHIBIT 99 ex_1005708.htm Exhibit 99 8285 El Rio, Suite 190 Houston, TX 77054 Phone 833.298.6633 NUO THERAPEUTICS ANNOUNCES SECOND QUARTER 2026 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE Differentiated Autologous PRP Remains Well-Positioned for Attracti
6 min readHOUSTON, April 29, 2025 ( GLOBE NEWSWIRE ) -- Nuo Therapeutics, Inc. ( OTCQB: AURX ) ( "Nuo" ) , a commercial stage medical device company pioneering leading-edge biodynamic therapies by focusing on emerging opportunities in the evolving healthcare landscape, announced it has entered into an ...
2 min read